Fulcrum Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Tourangeau Greg
Fulcrum Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Horn Patrick Taylor
Fulcrum Therapeutics | 3: Initial statement of beneficial ownership of securities-Officer Horn Patrick Taylor
Fulcrum Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Tourangeau Greg
Fulcrum Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Sapir Alex
Fulcrum Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Third Rock Ventures IV, L.P.(3.8%),Third Rock Ventures GP IV, L.P.(3.8%), etc.
Fulcrum Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-RA Capital Management, L.P.(18.8%),Peter Kolchinsky(18.8%), etc.
Fulcrum Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-RTW Investments, LP(8.8%),Roderick Wong, M.D.(8.8%)
Fulcrum Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Suvretta Capital Management, LLC(8.9%),Aaron Cowen(8.9%), etc.
Fulcrum Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-FMR LLC(9.195%),Abigail P. Johnson(9.195%)
Fulcrum Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Adage Capital Partners, L.P.(2.44%),Adage Capital Partners GP, L.L.C.(2.44%), etc.
Fulcrum Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Tourangeau Greg
Fulcrum Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Musso Alan A
Fulcrum Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Oltmans Curtis Gale
Fulcrum Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Musso Alan A
Fulcrum Therapeutics | 4: Statement of changes in beneficial ownership of securities-Chief Financial Officer Musso Alan A
Fulcrum Therapeutics | 3: Initial statement of beneficial ownership of securities-Chief Financial Officer Musso Alan A
Fulcrum Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-BlackRock, Inc.(2.5%)
Fulcrum Therapeutics | 3: Initial statement of beneficial ownership of securities-Officer Sapir Alex
Fulcrum Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director GERAGHTY JAMES A
No Data